Results 51 to 60 of about 4,245 (206)

Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT

EJNMMI Physics, 2020
Background Dead time may affect the accuracy of quantitative SPECT (QPSECT), and thus of dosimetry. The aim of this study was to quantify the effect of dead time on 177Lu-QSPECT and renal dosimetry following peptide receptor radionuclide therapy (PRRT ...
Alessandro Desy, Guillaume F. Bouvet, Andrea Frezza, Philippe Després, Jean-Mathieu Beauregard   +4 more
doaj   +1 more source

Clinical Utility of 68Ga‐DOTATOC Positron Emission Tomography/Computed Tomography in Evaluating Metastatic Lesions of Clear Cell Renal Cell Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction 68Ga‐DOTATOC positron emission tomography/computed tomography (PET/CT) targets somatostatin receptors (SSTRs) and is an established molecular imaging modality for neuroendocrine tumors (NETs). Although SSTR expression has been reported in renal cell carcinoma (RCC), its clinical utility remains unclear. Case Presentation A 76‐year‐
Yuta Mine, Toru Sakatani, Sho Koyasu, Takashi Ogata, Yuki Teramoto, Akio Sakamoto, Takashi Mizowaki, Yuji Nakamoto, Takashi Kobayashi, Takayuki Goto   +9 more
wiley   +1 more source

Peptide receptor radionuclide therapy.

, 2004
On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin. Changes in the density of these receptors during disease, for example, overexpression in many tumors, provide the basis for new ...
Kvols, LK, Krenning, Eric P, MARION DE JONG, De Jong, Marion, Pauwels, Stanislas, DIK J. KWEKKEBOOM, Kvols, Larry K, Krenning, Eric, Pauwels, S, Kwekkeboom, Dik J, ERIC P. KRENNING, Valkema, R., Jong, Marion, Valkema, Roelf, Kwekkeboom, Dik, ROELF VALKEMA, STANISLAS PAUWELS, LARRY K. KVOLS   +17 more
core   +1 more source

Metachronous occurrence of acute myeloid leukaemia in a case of neuroendocrine tumour

European Journal of Case Reports in Internal Medicine
Haematological neoplasms are rare in patients undergoing peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasms, though the long-term effects on bone marrow function remain an area of interest.
Abhinav Menon, Dilip Harindran Vallathol, Deepak Charles, Shagos Nair, Karthika Kundil Veetil, Ashok S. Komaranchath, Arun R. Warrier   +6 more
doaj   +1 more source

Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment

Journal of Neuroendocrinology, Volume 38, Issue 6, June 2026.
Abstract Neuroendocrine tumours (NETs) are well‐differentiated epithelial neuroendocrine neoplasms that frequently develop in the small intestine, pancreas, and lungs. NETs originate from neuroendocrine cells specialized in hormone secretion implicated in a number of physiological processes.
Victoria Jacquot, Benjamin Chevalier, Thomas Walter, Benjamin Gibert, Maria Ouzounova   +4 more
wiley   +1 more source

Peptide receptor radionuclide therapy of neuroendocrine tumours

, 2016
In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an
Brabander, Tessa, van Eijck, Casper, de Herder, W.W., Franssen, Gaston, Teunissen, Jaap, Feelders, R.A., Kwekkeboom, Dik   +6 more
core   +1 more source

Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

, 2020
Background Therapy-related leukemia is a well-recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic ...
Selin Kucukyurt, Ercaliskan, Abdulkadir, KABASAKAL, Levent, Levent Kabasakal, Ahmet Emre Eskazan, Yeliz Yagiz Ozogul, Kucukyurt, Selin, Abdulkadir Ercaliskan, EŞKAZAN, Ahmet Emre, Yagiz Ozogul, Yeliz   +9 more
core   +1 more source

Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report

BMC Neurology, 2023
Background Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis. Case presentation We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones ...
Dominik Lisowski, Philipp E. Hartrampf, Natalie Hasenauer, Vera Nickl, Camelia-Maria Monoranu, Jörg Tamihardja   +5 more
doaj   +1 more source

The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe

Crystals, 2021
Herewith, we report for the first time the crystal structure of tetrapeptide FwKT (Phe-D-Trp-Lys-Thr), which is considered to represent an epitope for biomedically relevant hormone somatostatin.
Sabina Diusenova, Sergey Arkhipov, Dmitry Avdeev, Pavel Dorovatovskii, Derenik Khachatryan, Vladimir Lazarenko, Michael Medvedev, Alena Nikolaeva, Mikhail Ovchinnikov, Maria Sidorova, Yan Zubavichus   +10 more
doaj   +1 more source

Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms

Cancer Medicine, Volume 15, Issue 5, May 2026.
NCCT radiomics for surufatinib efficacy prediction in HM‐NENs. ABSTRACT Background Hepatic metastatic neuroendocrine neoplasms (HM‐NENs) have few treatment biomarkers and low survival rates. We created a clinical‐radiomics fusion model based on non‐contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM‐NENs.
Miaomiao Feng, Man Zhao, Xiaoling Duan, Jiaojiao Hou, Qi Wang, Fei Yin   +5 more
wiley   +1 more source